Drug Information

Drug General Information
Drug ID
D0Z8RH
Former ID
DNC009065
Drug Name
2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529781]
Formula
C21H15F3N2
Canonical SMILES
C1=CC=C(C=C1)CN2C(=C3C=CC=C(C3=N2)C(F)(F)F)C4=CC=CC=C4
InChI
1S/C21H15F3N2/c22-21(23,24)18-13-7-12-17-19(18)25-26(14-15-8-3-1-4-9-15)20(17)16-10-5-2-6-11-16/h1-13H,14H2
InChIKey
LGRUCHCYEMOENE-UHFFFAOYSA-N
PubChem Compound ID
25137977
Target and Pathway
Target(s) Oxysterols receptor LXR-alpha Target Info Inhibitor [529781]
Oxysterols receptor LXR-beta Target Info Inhibitor [529781]
KEGG Pathway PPAR signaling pathway
Non-alcoholic fatty liver disease (NAFLD)
Hepatitis C
Pathway Interaction Database RXR and RAR heterodimerization with other nuclear receptorrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptor
Reactome Nuclear Receptor transcription pathway
WikiPathways Nuclear Receptors in Lipid Metabolism and Toxicity
Nuclear Receptors Meta-Pathway
PPAR Alpha Pathway
Liver X Receptor Pathway
Adipogenesis
SREBF and miR33 in cholesterol and lipid homeostasis
Nuclear ReceptorsWP1982:SREBP signalling
Nuclear Receptors
References
Ref 529781J Med Chem. 2008 Nov 27;51(22):7161-8.Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.
Ref 529781J Med Chem. 2008 Nov 27;51(22):7161-8.Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.